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Mutations in LRRK2 represent the most common causes of Parkinson’s disease (PD) identiﬁed to date, but their penetrance is
incompleteandprobablyduetothepresenceofothergeneticorenvironmentalfactorsrequiredfordevelopmentofthedisease.We
analyzed the presence of parkin sequence variants (mutations or polymorphisms) and exon rearrangements in LRRK2 mutations
carriers (both PD patients and unaﬀected relatives) in order to detect a possible modiﬁer eﬀect on penetrance. Eight families with
ninePDpatientswithheterozygousLRRK2mutations(identiﬁedwithin380SardinianPDpatientsscreenedforthepresenceofthe
ﬁve most common LRRK2 mutations) and sixteen additional relatives were genetically investigated for the presence of LRRK2 and
parkin mutations. No evidence was found for the presence of pathological parkin mutations or exon rearrangements in patients
or not aﬀected family members. Three single-nucleotide polymorphisms (SNPs) were identiﬁed both in patients and unaﬀected
relatives but did not signiﬁcantly diﬀer between the two groups. These data provide no support to the hypothesis whereby such
parkin gene mutations may be commonly implicated in possible eﬀect on penetrance in LRRK2 mutation carriers.
1.Introduction
Over the last few years several disease-causing genes have
been identiﬁed such as Mendelian forms of PD [1–5].
Mutations in Leucine-rich repeat kinase 2 (LRRK2)g e n e ,o n e
of the recently identiﬁed genes, cause autosomal dominant
PD [6, 7] and represent the most common causes of PD
identiﬁed to date [8–11]. A complete understanding of
how LRRK2 may lead to PD, with respect to other known
PD genes and putative pathogenic pathways, is still elusive
[12]. Besides, penetrance of LRRK2 mutations is incom-
plete [13–15] and probably due to the presence of other
genetic or environmental factors required for development
of the disease. Previous ﬁndings reported an interesting and
unexpected interaction of LRRK2 with parkin, suggesting
that a direct interaction between these two genetic causes
of parkinsonism may be involved in a common pathogenic
pathway [16]. In recent studies, moreover, parkin mutations
were identiﬁed in a few patients carrying the LRRK2-
G2019S mutation [17–19], suggesting a possible digenic
mechanism of PD inheritance [18]. Here, we analyzed the
presence of parkin sequence variants (point mutations or
polymorphisms) and exon rearrangements in patients with
Parkinson’s disease (PD) having LRRK2 mutations and in
LRRK2 mutations carriers family members without sign of
PD in order to detect possible eﬀect on penetrance.2 Parkinson’s Disease
Table 1: Oligonucleotides used for the ASOs technique. The nucleotide change in the oligonucleotides is underlined.
Exon 31 1441 wild-type allele R 5 -CCCTCCAGGCTCGCGCTTC-3 
1441 mutant allele C 5 -CCCTCCAGGCTTGCGCTTC-3 
1441 mutant allele G 5 -CCCTCCAGGCTGGCGCTTC-3 
1441 mutant allele H 5 -CCCTCCAGGCTCACGCTTC-3 
Exon 41 2019 wild-type allele G 5 -AAAGATTGCTGACTACGGCA-3
2019 mutant allele S 5 -AAAGATTGCTGACTACAGCA-3 
2020 wild-type allele I 5 -GCATTGCTCAGTACTGCTGT-3 
2020 mutant allele T 5 -GCACTGCTCAGTACTGCTGT-3 
2.SubjectsandMethods
Three hundred and eighty Sardinian PD unrelated patients
and two hundred and eight controls subject, consecutively
recruited both from the Movement Disorders Centre of
the Cagliari’s University Hospital and from the Department
of Neurology of the University Policlinic of Monserrato,
were screened for the presence of the ﬁve most common
LRRK2 mutations (G2019S, I2020T, and R1441C/G/H).
ProbandswithevidenceofLRRK2mutationswereidentiﬁed.
Subsequently, these patients and their respective families
were clinically studied. The probands were examined at the
study site and additional family members were recruited
by means of the probands. Family members who agreed
to undergo genetical analysis were investigated for LRRK2
mutations. Besides, both in patients and in family members,
all exons of the parkin gene were analyzed for small
deletions, point mutations, and rearrangements. PD patients
fulﬁlled the diagnostic criteria for a clinical diagnosis of
deﬁned PD with at least three of the mandatory criteria
(resting tremor, akinesia, and rigidity), improvement with
levodopa, asymmetrical onset, and the absence of exclusion
criteria. The institutional authorities at each participating
site approved the study, and written informed consent was
obtained from all participants.
Genomic DNA was extracted from peripheral blood
samples using standard procedure. To detect the presence
of the R1441C/G/H (exon31), G2019S, and I2020T (exon
41) mutations, the samples were ampliﬁed by polymerase
chain reaction (PCR) using the following primers (5  to
3 ): Exon 31 Forward: TCTGAAGTCTGCTAGTTTCTC and
Reverse: CTGACATTTCTAGGCAGTTG; Exon 41 Forward:
GAGCACAGAATTTTTGATGCTTG and Reverse: TTTATC-
CCCATTCCACAGCAGTAC. PCR reactions were done in
50μl containing 1X Gold PCR buﬀer, 1.5mM MgCl2,
250μM dNTPs, 25 pmoles of each primer, 2 units of
AmpliTaqGold(AppliedBiosystems),and100ngofgenomic
DNA. Cycle conditions were 11min at 94
◦C; 30 cycles
of 30-second denaturation at 94
◦C; 45-second annealing
at 58
◦C for exon 31 and 60
◦C for exon 41; 90-second
extension at 72
◦C and a ﬁnal extension of 7min at 72
◦C.
After the sizing, PCR products were denatured and blotted
into Hybond-N+ membranes (Amersham Biosciences). The
blotswereprehybridized,hybridizedwith[32P]CTPlabeled-
probes listed below for 1 h, washed, and exposed to
Kodak XAR ﬁlm. All the steps were performed at the
speciﬁc temperatures and time. Oligonucleotides used for
the ASOs technique are indicated in Table 1.H e t e r o z y g o u s
samples for LRRK2 mutations (R1441C or S2019G) were
conﬁrmed by PCR-RFLP using the speciﬁc endonucleases
BstUI and SfcI according to the Manufacturing guides.
Samples showing the loss of BstUI restriction site for
R1441 were resolved by direct sequencing to identify the
exact codon. The sequencing was performed using sense
and antisense primers on a MEGABACE 1000 (Amersham)
and results analysed with a MegaBace Sequencing Analyzer
v3.0.
In all subjects coming from families with presence of
LRRK2mutations,parkinmutations analysiswasperformed.
All 12 exons of parkin and their intron-exon boundaries
were screened for point mutations and small deletions by
directPCRsequencing.Thesequencingwasperformedusing
sense and antisense primers previously described [20]o na
MEGABACE 1000 (Amersham) and results analysed with a
MegaBace Sequencing Analyzer v3.0.
Parkin exon rearrangements were also examined. Two
commercially available probe kits, SALSA P051-C1 and
P052-C1 Parkinson MLPA kits (MRC Holland, Amsterdam,
The Netherlands; http://www.mlpa.com), were used for this
assay. All exons of parkin were included in both kits,
and the probe sequences of the same exon were diﬀerent
between the two kits. The assay was performed for all
the 25 samples according to the manufacturer’s protocol.
After MLPA treatment, samples were run on an ABI 3130xl
Genetic Analyzer (Applied Biosystems) with GeneScan-500
LIZ Size Standard (Applied Biosystems) according to the
manufacturer’s recommendations. Data were analyzed using
GeneMapper software v4.0 (Applied Biosystems). Electro-
pherograms were ﬁrst visually analyzed to discard failed
samples. Thereafter, peak height results were exported from
Gene-Mapper to Coﬀalyser v9 software. Coﬀalyser is an
Excel-based program which runs on a Microsoft Oﬃce 2003
and recommended by MRC Holland. After normalization
of data by Coﬀalyser macro, comparing the peak pattern
obtained to that of reference samples, we obtain samples
carrying aberrant copy numbers. In the Coﬀalyser analysis,
a peak size indicates a normal copy number when showing a
0.7–1.3 ratio compared to normal controls, a deletion when
showing a ratio <0.7, again when showing a ratio >1.3, and
an absence when showing a ratio equal to 0. Based on this
correlation, a normal peak indicates the presence of two gene
copies.Parkinson’s Disease 3
Table 2: Study of families with LRRK2 mutations.
Subjects with PD Patients with LRRK2
mutations
Not aﬀected relatives with
LRRK2 mutations
Not aﬀected relatives without
LRRK2 mutations
G2019S 71 03
Mutation ( 5M / 2F ) ( 4M / 6F ) ( 1M / 2F )
R1441C 203
Mutation (2 F) (2 M/1 F)
Total 91 06
(25) ( 5M / 4F ) ( 4M / 6F ) ( 3M / 3F )
M :M a l e ;F :F e m a l e .
Table 3: Allele and genotype frequency distribution of three single-nucleotide polymorphisms of the parkin gene in carriers of LRRK2
mutations (R1441C or G2019S) with or without PD.
Polymorphism R1441C Aﬀected G2019S Aﬀected Total R1441 or
G2019 Aﬀected
G2019S Healthy P =
rs2075923 IVS2+25T→C
Allele T 2 9 11 16
.243
Allele C 2 5 7 4
Genotype TT [Mean AO or AE ± SD (ys)] 0 3 [65.5 ± 9.0] 3 [65.5 ± 9.0] 7 [67.7 ± 9.9]
Genotype TC [Mean AO or AE ± SD (ys)] 2 [67.8 ± 7.5] 3 [78.7 ± 4.2] 5 [74.4 ± 6.6] 2 [68.2 ± 8.2]
Genotype CC [Mean AO or AE ± SD (ys)] 0 [NV] 1 [77.2] 1 [77.2] 1 [69.7]
rs3765474 IVS7−35G→A
Allele G 2 8 10 11
.550
Allele A 2 6 8 9
Genotype GG [Mean AO or AE ± SD (ys)] 1 [60] 2 [73.9 ± 1.4] 3 [65.5 ± 4.9] 2 [73.4 ± 0.7]
Genotype GA [Mean AO or AE ± SD (ys)] 0 4 [64.3 ± 15.9] 4 [64.3 ± 15.9] 7 [67.2 ± 9.7]
Genotype AA [Mean AO or AE ± SD (ys)] 1 [65] 1 [59] 2[ 6 2± 4.2] 1 [62.5]
EX10 c.1239G>C Val380Leu
Allele G 3 11 14 14
.656
Allele C 1 3 4 6
Genotype GG [Mean AO or AE ± SD (ys)] 1 [60] 4 [61.3 ± 13.7] 5 [61.0 ± 11.9] 4 [60.9 ± 7.7]
Genotype GC [Mean AO or AE ± SD (ys)] 1 [59] 3 [77 ± 5.4] 4 [74.8 ± 6.2] 6 [72.7 ± 5.5]
Genotype CC [Mean AO or AE ± SD (ys)] 0 0 0 0
AO: age at disease onset; AE: age at examination; SD: Standard deviation; ys: years.
Statistical analysis concerning polymorphisms of the
parkin gene were compared between PD patients having
LRRK2 mutations and LRRK2 mutations carriers family
members without sign of PD with the Fisher’s exact prob-
ability test.
3. Results
Eight families (six of them carrying the G2019S mutations
and two carrying the R1441C mutations) with nine PD
patients heterozygous carriers of LRRK2 mutations were
identiﬁed. Of these nine patients (mean PD onset 63.6 ±
10.2 years, range 44–77), seven individuals (ﬁve males and
two females) carried the LRRK2 G2019S substitution and
two females carried the R1441C substitution. The mean
duration of disease in years for aﬀected individuals was 8.2 ±
3.5 years (range: 1–12). Sixteen not aﬀected proband family
members (13 within families with G2019S mutation and
3 with R1441C mutation) with mean age at examination
68.6 ± 9,2 years (range, 51–83) agreed to undergo analysis
for LRRK2 mutations, ten of whom (four males and six
females) were found to be G2019S heterozygous carriers
with no sign of PD (Table 2). No evidence was found
for the presence of pathological parkin point mutations in
anyone of the 25 subjects examined, either in PD patients
or in not aﬀected family members. Three single-nucleotide
polymorphisms (SNPs) were identiﬁed: two of these SNPs
reside within the intronic sequences (IVS2 + 25T > C =
rs2075923 and IVS7 − 35G > A = rs3765474) while the
thirdwastheVal380Leupolymorphismsinexon10.Allthese
SNPs were identiﬁed both in patients and not aﬀected family
members (Table 3). Fisher’s exact probability test showed
that the allele and genotype frequencies of each detected
Parkin SNPs did not signiﬁcantly diﬀer between the group of
PD patients with LRRK2 mutations and not aﬀected family
members with LRRK2 mutations. MLPA analysis disclosed4 Parkinson’s Disease
no chromosomal rearrangement for the parkin gene in the
25 patients conﬁrmed in both SALSA P051-C1 and P052-C1
being ratio comprises between the cut-oﬀ values.
4. Discussion
To our knowledge, this is the ﬁrst study which attempts to
study the reduced penetrance of LRRK2 mutations analyzing
a possible digenic mechanism of PD inheritance with parkin
mutations,studyingbothPDpatientswithLRRK2mutations
and not aﬀected family members with LRRK2. The detection
in our families of at least ten subjects carrying the G2019S
mutation in heterozygous state, with mean age at examina-
tion near to 68 years, but without any sign of PD, clearly
conﬁrmed previous observations which describe penetrance
ofLRRK2mutationsaslowandincomplete[13–15].Besides,
a complete understanding of how LRRK2 gene mutation
causes PD, or where it ﬁts with respect to other known PD
genes and putative pathogenic pathways, is still elusive [12].
Inthisscenario,boththereportedinteractionofLRRK2with
parkin [16] and the recent observations of several subjects
simultaneouslyharboringbothLRRK2andPRKN mutations
[17–19] have invited to consider a potential genetic interplay
between these two most common genetic causes of parkin-
sonism in the mechanisms of penetrance, with a model of
gene–gene interaction. Although two previous articles have
studied this combination [18, 19], they only concentrated
their attention on age at onset or progression of disability,
examining mainly clinical ﬁndings of PD patients, without
a complete clinical and genetic familiar analysis. In fact, the
ﬁrst paper [18], involving 9 patients with G2019S mutations
and10withR1441Gmutations(detectedamong351patients
with idiopathic PD), concluded that three detected patients
harboring double mutation did not present an earlier age-at-
onset or a faster progression of disease. Unfortunately, in this
study a genetic analysis of the LRRK2 mutations in relatives
of these patients was not performed. In the second paper
[19], regarding 138 Portuguese PD patients, 13 patients with
LRRK2 mutations (10 probands and 3 aﬀected relatives)
were identiﬁed and 2 of them carried a single heterozygous
mutation in the parkin gene. Owing to the fact that the
detected parkin mutation did not cosegregate in one family
with PD and the PD onset age in these two siblings with
and without parkin mutation was similar, these authors
concluded that the presence of parkin mutations could be
a coincidental ﬁnding, but a modiﬁer eﬀect on penetrance
was not analyzed because also in this report other relatives of
these patients were not studied from a genetic point of view.
Diﬀerently from these studies, therefore, the aim of
our analysis was not to verify if patients with possible
contemporary presence of LRRK2 mutations and parkin
mutations could present an earlier age-at-onset or a faster
progression of disease, but, more precisely, if presence of
this combination could have inﬂuenced the penetrance
of PD in these patients. To this regard, our ﬁndings do
not conﬁrm the presence of parkin point mutations, small
deletions, or exon rearrangements in our patients with
LRRK2 mutations. In fact, we did not ﬁnd any pathogenic
parkin mutations in any subjects of the 8 studied families
carriers of LRRK2 mutations. Moreover, we did not ﬁnd any
associations between three diﬀerent polymorphisms of the
parkingeneandthereducedpenetranceofLRRK2mutations
in these families, indicating that parkin mutations are not
commonly involved in determining the pathogenesis of PD
in these patients. Our data, together with the two previous
studies [18, 19], exclude the occurrence of pathogenic parkin
mutations in the majority of PD patients with LRRK2
substitutions.
In conclusion, our ﬁndings do not provide support to
the hypothesis whereby parkin gene mutations may be com-
monly implicated in possible modiﬁer eﬀect on penetrance
in LRRK2 mutation carriers.
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